Dunad Therapeutics

Its proprietary small molecule platform is designed to discover and develop novel therapeutics that are orally bioavailable with improved specificity and pharmacologic features that advance the frontiers of protein degradation therapies.

In 2021, Dunad entered a strategic collaboration with Novartis to develop next-generation therapies in a deal worth $24 million in an upfront payment with equity investment plus significant research funding. Dunad was also eligible for milestone payments with an aggregate value of up to $1.3billion (plus royalties).

Dunad has operations in Cambridge, UK and Cambridge, Massachusetts. Its investors include Alpha Wave, BGV, Epidarex Capital, Novartis and Wellington Partners.